<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02251210</url>
  </required_header>
  <id_info>
    <org_study_id>543.27</org_study_id>
    <nct_id>NCT02251210</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of BIIL 284 BS in Adult Patients With Active Rheumatoid Arthritis</brief_title>
  <official_title>Three Month, Randomised, Double-blind, Double-dummy, Placebo-controlled, Multiple Dose-range Study of the Efficacy and Safety of BIIL 284 BS (5, 25 and 75 mg p.o. Once Daily) in Adult Patients With Active Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To investigate efficacy and safety of 3 doses of BIIL 284 BS in active rheumatoid arthritis
      (RA) and determine the dose with most positive efficacy / safety ratio. Pharmacokinetic
      profile will be also obtained.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2001</start_date>
  <primary_completion_date type="Actual">November 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients achieving 20% improvement assessed by the American College of Rheumatology (ACR) criteria (ACR20)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving 50% improvement (ACR50)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of withdrawals due to lack of efficacy</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of swollen joints</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of tender joints</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's assessment of pain on a visual analog scale (VAS)</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's global assessment of disease activity by VAS</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator's global assessment of disease activity by VAS</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's assessment of physical function</measure>
    <time_frame>up to 3 months</time_frame>
    <description>via Health Assessment Questionnaire (HAQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in erythrocyte sedimentation rate (ESR)</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C-reactive protein (CRP)</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>baseline, 3 months</time_frame>
    <description>assessed by the SF-36 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Disease Activity Score (DAS 28)</measure>
    <time_frame>baseline, up to 3 months</time_frame>
    <description>Disease Activity Score in 28-joint count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in duration of morning stiffness</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of rescue medication</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of withdrawals due to adverse events</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final global assessment of tolerability by investigator on a 4-point scale</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's assessment of fatigue by VAS</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes in laboratory findings</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes in vital signs</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes in 12-lead ECG</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">404</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>BIIL 284 BS low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BIIL 284 BS medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BIIL 284 BS high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIIL 284 BS low dose</intervention_name>
    <arm_group_label>BIIL 284 BS low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIIL 284 BS medium dose</intervention_name>
    <arm_group_label>BIIL 284 BS medium dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIIL 284 BS high dose</intervention_name>
    <arm_group_label>BIIL 284 BS high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of &gt;=18 and &lt;= 70 years of age

          -  Patients suffering from rheumatoid arthritis as defined by the American Rheumatism
             Association (ARA) criteria revised 1987 and date of diagnosis &gt;= 6 months. At least 4
             of the following 7 criteria must be present:

               -  Morning stiffness in and around the joints lasting at least 1 hour before maximal
                  improvement for at least 6 weeks

               -  Arthritis (soft tissue thickening or fluid - not bony overgrowth alone) of at
                  least 3 joint areas for at least 6 weeks

               -  Arthritis of hand joints (at least one area swollen in a wrist,
                  metacarpophalangeal (MCP) or proximal interphalangeal (PIP) joint) for at least 6
                  weeks

               -  Symmetrical arthritis (observed by a physician) with simultaneous involvement of
                  the joints on both sides of the body for at least 6 weeks

               -  Rheumatoid nodules (observed by a physician) over bony prominence or extensor
                  surfaces or in juxta-articular regions

               -  Serum rheumatoid factor positive

               -  X-ray changes typical of rheumatoid arthritis (erosions or unequivocal bony
                  decalcification localized in or most marked adjacent to the involved joints)

          -  Patients belonging to the RA functional class I, II or III

          -  Active RA as defined at visit 2 by:

               -  Swollen joint count at least of 6 (of 28 joints examined) and

               -  Tender joint count at least of 8 (of 28 joints examined) and

               -  Patients must fulfil 2 out of the 3 following criteria:

                    -  Patient's assessment of pain (VAS) &gt;= 40 mm

                    -  Investigator's global assessment of disease activity on a VAS &gt;= 40 mm

                    -  ESR &gt;= 28 mm/h or CRP &gt;= 20 mg/L

          -  Patient's written informed consent obtained at Visit 1 (screening) before enrolment in
             the study

        Exclusion Criteria:

          -  Patient presenting or having a history of inflammatory rheumatic disease other than RA
             (e.g.: mixed connective tissue disease, systemic lupus erythematosus, seronegative
             spondyloarthropathy)

          -  Patients who have failed to more than 3 different disease-modifying antirheumatic drug
             (DMARDs) therapies previously due to lack of efficacy (in case of combined therapy
             each DMARDs used is counted as one)

          -  Patients with any other disease that could interfere with the evaluation of efficacy
             and safety

          -  Patients in treatment with any DMARDs / slow-acting anti-rheumatic drug (SAARDs)
             during the periods specified:

               -  4 weeks before V2: Methotrexate, parenteral/oral gold, D-penicillamine,
                  Sulphasalazine, antimalarials (e.g.:Chloroquine/Hydroxychloroquine),
                  Azathioprine, Cyclosporine A, Alkylating agents (e.g.: Cyclophosphamide /
                  Chlorambucil), Minocycline, Etanercept (Enbrel®), and Leflunomide (only if
                  wash-out with Colestyramine has been done after leflunomide discontinuation)

               -  3 months before Visit 2: Leflunomide if no wash- out with colestyramine has been
                  done after leflunomide discontinuation, Infliximab (Remicade®), any other
                  biological compound.

          -  Patient in treatment with oral corticosteroids at a dose higher than 10 mg/day or 0.2
             mg/Kg/day (prednisone equivalent) whichever is lower, during the 4 weeks prior to
             Visit 2, change in the treatment with oral corticosteroids during the 4 weeks prior to
             Visit 2 or intended change during the trial

          -  Patients in treatment with any parenteral (intravenous, intramuscular or
             intraarticular) treatment with corticosteroids during the 4 weeks prior to Visit 2 or
             their intended use during the trial.

          -  Change in treatment with non-steroidal anti-inflammatory drugs (NSAIDs) during the 2
             weeks prior to Visit 2 or any intended change during the trial.

          -  Synovectomy, and/or surgical treatment for RA in the previous 3 months prior to visit
             2 or intended indication during the trial.

          -  Synoviorthesis in the previous 4 weeks prior to Visit 2 or intended indication during
             the trial.

          -  Patients in treatment with any other leukotriene inhibitors such as montelukast or
             zafirlukast 4 weeks prior to Visit 2 or intended use during the trial.

          -  Initiation of physiotherapy during the 2 weeks before V2, or intended change during
             the trial

          -  Patients with history of cardiovascular, renal, neurologic, psychiatric, liver,
             gastrointestinal (including lactose intolerance ), immunologic or endocrine
             dysfunction if they are clinically significant.

          -  Patients with any other known condition or circumstance, which would in the
             investigator's opinion, prevents compliance or completion of the study

          -  Patients with history of cancer within the past 5 years, excluding treated basal cell
             carcinoma

          -  Patients with chronic infection or acute infections during the 4 weeks before visit 1

          -  Patients with known positive serology for hepatitis B or C

          -  Patients with anticoagulant treatment (i.e. dicumarol or derivatives, warfarin)

          -  Any of the following abnormal laboratory parameters at Visit 2:

               -  Impaired hepatic function, defined by serum levels of either Aspartate
                  Aminotransferase (AST)(SGOT), Alanine Aminotransferase (ALT) (SGPT), alkaline
                  phosphatase or bilirubin &gt; 2 x upper limit of normal (ULN)

               -  Impaired renal function, defined by serum creatinine &gt; 133 mmol/L (1.5 mg/dl)

               -  Hemoglobin values &lt; 10 g/dl

               -  White blood cell count &lt;= 3.500 cells/mm3

               -  Platelet count of less than 120.000/mm3

               -  Severe hypoproteinemia (e.g. in case of severe liver disease or nephrotic
                  syndrome) with albumin &lt; 3.0 g/dl

          -  Patients with any other abnormal, clinically relevant laboratory values not related to
             RA

          -  Patients participating in another clinical trial during the 3 months prior to visit 2

          -  Previous participation in the randomised period of this study

          -  Patients with a significant history and/or active alcohol or drug abuse Significant is
             defined as that which in the opinion of the investigator may either put the patient at
             risk because of participation in the study or may influence the results of the study
             or the patient's ability to participate in the study

          -  Pregnancy (to be excluded by pregnancy test at visit 1) or breast feeding, and
             sexually active women with childbearing potential not using a medically approved
             method of contraception (i.e. oral contraceptives, intrauterine devices, or
             double-barrier) for at least one month before and throughout the study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2014</study_first_submitted>
  <study_first_submitted_qc>September 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2014</study_first_posted>
  <last_update_submitted>September 25, 2014</last_update_submitted>
  <last_update_submitted_qc>September 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

